版權(quán)說明：本文檔由用戶提供并上傳，收益歸屬內(nèi)容提供方，若內(nèi)容存在侵權(quán)，請(qǐng)進(jìn)行舉報(bào)或認(rèn)領(lǐng)
文檔簡(jiǎn)介
1、ReferencenumberISO14155:2011(E)?ISO2011INTERNATIONALSTARDISO14155Secondedition20110201Clinicalinvestigationofmedicaldevicesfhumansubjects—GoodclinicalpracticeInvestigationcliniquedesdispositifsmdicauxpoursujetshumains—Bo
2、nnespratiquescliniquesCopyrightInternationalganizationfStardizationProvidedbyIHSunderlicensewithISONotfResaleNoreproductionwkingpermittedwithoutlicensefromIHS``````````````ISO14155:2011(E)?ISO2011–AllrightsreservediiiCon
3、tentsPageFewd.............................................................................................................................................................v1Scope...........................................
4、...........................................................................................................12Nmativereferences..............................................................................................
5、..............................13Termsdefinitions...........................................................................................................................24Ethicalconsiderations..........................
6、................................................................................................74.1General.................................................................................................................
7、..................................74.2Improperinfluenceinducement......................................................................................................84.3Compensationadditionalhealthcare.................
8、.........................................................................84.4Responsibilities...............................................................................................................................
9、......84.5Communicationwiththeethicscommittee(EC)................................................................................84.5.1General..............................................................................
10、.....................................................................84.5.2InitialECsubmission............................................................................................................................84
11、.5.3InfmationtobeobtainedfromtheEC..............................................................................................94.5.4ContinuingcommunicationwiththeEC......................................................
12、.......................................94.5.5ContinuinginfmationtobeobtainedfromtheEC.........................................................................94.6Vulnerablepopulations.....................................
13、....................................................................................94.7Infmedconsent.......................................................................................................................
14、.........104.7.1General.................................................................................................................................................104.7.2Processofobtaininginfmedconsent..............
15、..............................................................................104.7.3Specialcircumstancesfinfmedconsent..................................................................................104.7.4Infmationtob
16、eprovidedtothesubject........................................................................................114.7.5Infmedconsentsignature..................................................................................
17、.............................134.7.6Newinfmation..................................................................................................................................135Clinicalinvestigationplanning..........
18、................................................................................................145.1General................................................................................................................
19、.................................145.2Riskevaluation....................................................................................................................................145.3Justificationfthedesignofthecli
20、nicalinvestigation.................................................................145.4Clinicalinvestigationplan(CIP)......................................................................................................
21、...145.5Investigatsbrochure(IB)................................................................................................................155.6Casereptfms(CRFs).......................................................
22、............................................................155.7Monitingplan....................................................................................................................................155.8Invest
23、igationsiteion................................................................................................................155.9Agreement(s).............................................................................
24、..........................................................155.10Labelling...............................................................................................................................................155.
25、11Datamonitingcommittee(DMC)....................................................................................................166Clinicalinvestigationconduct.............................................................
26、..............................................166.1General.................................................................................................................................................166.2Investigatio
27、nsiteinitiation.................................................................................................................166.3Investigationsitemoniting..............................................................
28、...............................................166.4Adverseeventsdevicedeficiencies...........................................................................................166.4.1Adverseevents..........................
29、..........................................................................................................166.4.2Devicedeficiencies.........................................................................................
30、....................................166.5Clinicalinvestigationdocumentsdocumentation....................................................................176.5.1Amendments...................................................
31、.....................................................................................176.5.2Subjectidentificationlog........................................................................................................
32、............176.5.3Sourcedocuments..............................................................................................................................176.6Additionalmembersoftheinvestigationsiteteam............
33、.............................................................176.7Subjectprivacyconfidentialityofdata......................................................................................176.8Documentdatacontrol.........
34、.......................................................................................................18CopyrightInternationalganizationfStardizationProvidedbyIHSunderlicensewithISONotfResaleNoreproductionwkingpermitted
溫馨提示
- 1. 本站所有資源如無特殊說明，都需要本地電腦安裝OFFICE2007和PDF閱讀器。圖紙軟件為CAD,CAXA,PROE,UG,SolidWorks等.壓縮文件請(qǐng)下載最新的WinRAR軟件解壓。
- 2. 本站的文檔不包含任何第三方提供的附件圖紙等，如果需要附件，請(qǐng)聯(lián)系上傳者。文件的所有權(quán)益歸上傳用戶所有。
- 3. 本站RAR壓縮包中若帶圖紙，網(wǎng)頁內(nèi)容里面會(huì)有圖紙預(yù)覽，若沒有圖紙預(yù)覽就沒有圖紙。
- 4. 未經(jīng)權(quán)益所有人同意不得將文件中的內(nèi)容挪作商業(yè)或盈利用途。
- 5. 眾賞文庫僅提供信息存儲(chǔ)空間，僅對(duì)用戶上傳內(nèi)容的表現(xiàn)方式做保護(hù)處理，對(duì)用戶上傳分享的文檔內(nèi)容本身不做任何修改或編輯，并不能對(duì)任何下載內(nèi)容負(fù)責(zé)。
- 6. 下載文件中如有侵權(quán)或不適當(dāng)內(nèi)容，請(qǐng)與我們聯(lián)系，我們立即糾正。
- 7. 本站不保證下載資源的準(zhǔn)確性、安全性和完整性, 同時(shí)也不承擔(dān)用戶因使用這些下載資源對(duì)自己和他人造成任何形式的傷害或損失。
最新文檔
- iso7010-2011
- iso 10271-2011
- iso 37-2011
- iso 294-5-2011
- iso 1043-1-2011
- iso ts 16181-2011
- iso 11148-9-2011
- din en iso 22434-2011
- din en iso 2702-2011
- din en iso 14583-2011
- din en iso 11591-2011
- bs en iso 8502-9-2011
- din en iso 13982-1-2011
- din en iso 28706-2-2011
- bs en iso 11296-4-2011
- iso15378 2011 (din en iso 15378 2012) 檢查清單
- bs en iso 12543-2-2011
- iso 12402-8 amd 1-2011
- din en iso 12402-8-a1 2011
- 元雜劇中的俠形象研究_14155.pdf
評(píng)論
0/150
提交評(píng)論